GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Debt-to-EBITDA

Proteomics International Laboratories (ASX:PIQ) Debt-to-EBITDA : -0.01 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Proteomics International Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.04 Mil. Proteomics International Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.01 Mil. Proteomics International Laboratories's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-7.23 Mil. Proteomics International Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Proteomics International Laboratories's Debt-to-EBITDA or its related term are showing as below:

ASX:PIQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.28   Med: -0.19   Max: -0.01
Current: -0.01

During the past 9 years, the highest Debt-to-EBITDA Ratio of Proteomics International Laboratories was -0.01. The lowest was -1.28. And the median was -0.19.

ASX:PIQ's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs ASX:PIQ: -0.01

Proteomics International Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Proteomics International Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories Debt-to-EBITDA Chart

Proteomics International Laboratories Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.09 -0.10 -0.03 - -0.01

Proteomics International Laboratories Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - - -0.01 -0.01

Competitive Comparison of Proteomics International Laboratories's Debt-to-EBITDA

For the Biotechnology subindustry, Proteomics International Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteomics International Laboratories's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's Debt-to-EBITDA falls into.



Proteomics International Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Proteomics International Laboratories's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.031 + 0.034) / -8.287
=-0.01

Proteomics International Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.035 + 0.011) / -7.234
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Proteomics International Laboratories  (ASX:PIQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Proteomics International Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteomics International Laboratories (ASX:PIQ) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories (ASX:PIQ) Headlines

No Headlines